Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet

The molecular model of cholesterol/randomly methylated b cyclodextrin

IJMS, Free Full-Text

Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation

Frontiers Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment

Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation

Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect

Predicting the Binding Mode of 2-Hydroxypropyl-β-cyclodextrin to Cholesterol by Means of the MD Simulation and the 3D-RISM-KH Theory

Biomolecules, Free Full-Text

Frontiers Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk

Predicting the Binding Mode of 2-Hydroxypropyl-β-cyclodextrin to Cholesterol by Means of the MD Simulation and the 3D-RISM-KH Theory